CSL gene therapy gets second tick

By Megan Brodie 2 years ago | In Companies, Regulatory
  • 2 years ago

18 December 2022 The EMA has followed the FDA in recommending CSL’s HEMGENIX (etranacogene dezaparvovec)…

This is subscriber-only content. Please login to continue reading.